ZyVersa Therapeutics, Inc. (ZVSA)
(Delayed Data from NSDQ)
$3.02 USD
+0.37 (13.96%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ZVSA 3.02 +0.37(13.96%)
Will ZVSA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVSA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for ZVSA
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024
ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
ZyVersa Therapeutics announces publication of data on extracellular ASC